Everolimus With and Without Temozolomide in Adult Low Grade Glioma

NCT02023905 | Terminated Phase 2 Results DMC FDA Drug

• 3 other identifiers: Novartis-CRAD001CUS225T131012NCI-2014-00749
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells from growing and multiplying. Specifically, there is a protein called mTOR that we think helps many tumors to grow, and everolimus blocks the effect of mTOR. Temozolomide is also an anticancer agent that prevents tumor cells from growing and multiplying.

Conditions

Low Grade Glioma; World Health Organization (WHO) Grade II Astrocytomas; Oligodendrogliomas; Mixed Oligoastrocytomas

Outcome Measures

Primary Outcomes (2)

• Progression-Free Survival Rate (PFS) (Arms 1 and 2)

  Participants will be analyzed based on intention to treat using the Response Assessment in Neuro-Oncology (RANO) criteria for progression. Based on RANO criteria, a responder is defined using both radiographic and clinical criteria. Complete response (CR) or Partial Response (PR) will be first assessed by radiographic changes as determined by an improvement of the bi-dimensional evaluation of the tumor size. In addition, changes in neurologic function and steroid use will be considered. Analyses will be performed after all enrolled participants in arm 1 or arm 2 have completed 33 months on study, or whenever the progression status of all participants has been established, whichever comes first. Kaplan-Meier estimates and the associated 95% confidence intervals (CI) will be calculated for the 33-month PFS separately for the two arms.

  Up to 33 Months

• Progression-Free Survival Rate (PFS) (Arm 3)

  Participants will be analyzed based on intention to treat using the Response Assessment in Neuro-Oncology (RANO) criteria for progression. Based on RANO criteria, a responder is defined using both radiographic and clinical criteria. Complete response (CR) or Partial Response (PR) will be first assessed by radiographic changes as determined by an improvement of the bi-dimensional evaluation of the tumor size. In addition, changes in neurologic function and steroid use will be considered. Analyses will be performed after all participants enrolled in arm 3 have completed 38 months on study, or whenever the progression status of all participants has been established, whichever comes first. Kaplan-Meier estimates and the associated 95% CIs will be calculated for the 38-month PFS.

  Up to 38 Months

Secondary Outcomes (4)

• Median Progression Free Survival (PFS)

  Up to 84 Months

• Overall Survival Rate (OS)

  Up to 84 Months

• Objective Response Rate (ORR)

  Up to 36 Months

• Rate of Reduction in Seizures

  Up to 36 Months

Study Arms (3)

Arm 1: Everolimus

EXPERIMENTAL

If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is present, patients will be treated with single-agent everolimus at 10 mg daily continuously for up to 24 cycles, after which patients will be followed with interval MRIs until progression.

Drug: Everolimus

Arm 2: Everolimus and Temozolomide

EXPERIMENTAL

If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is not present, patients will be treated with combined everolimus and Temozolomide (TMZ). Everolimus will be given at 10 mg daily continuously for up to 24 cycles, and Temozolomide will be dosed initially at 150 mg/m\^2 per day for 5 days out of a 28-day cycle for up to 12 cycles, after which patients will be followed with interval MRIs until progression.

Drug: Everolimus; Drug: Temozolomide

Arm 3: Everolimus (1p/19q co-deletion present)

EXPERIMENTAL

If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If 1p/19q co-deletion is present, patients will be treated with single-agent everolimus at 10 mg daily continuously for up to 24 cycles, after which patients will be followed with interval MRIs until progression.

Drug: Everolimus

Interventions

Everolimus DRUG

everolimus at 10 mg daily continuously

Also known as: RAD001, Afinitor

Arm 1: Everolimus; Arm 2: Everolimus and Temozolomide; Arm 3: Everolimus (1p/19q co-deletion present)

Temozolomide DRUG

Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles

Also known as: Temodar, TMZ

Arm 2: Everolimus and Temozolomide

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>= 18 years
• Karnofsky performance scale score (KPS) \>= 60
• Adequate bone marrow function as shown by: Absolute Neutrophil Count (ANC) \>= 1.5 x 10\^9/L, Platelets \>= 100 x 10\^9/L, hemoglobin \>= 9.0 g/dL;
• Adequate liver function as shown by: Total serum bilirubin ≤ 2.0 mg/dL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=2.5x upper limit of normal (ULN), International Normalized Ratio (INR) \<= 2;
• Adequate renal function: serum creatinine \<=1.5 x ULN;
• Fasting serum cholesterol \<= 300 mg/dL OR \<= 7.75 mmol/L AND fasting triglycerides \<= 2.5x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication with confirmed reduction of lab values to within eligibility parameters;
• Signed informed consent prior to any screening procedures
• Histologically proven supratentorial low-grade glioma at initial diagnosis; pathology must have been reviewed by University of California, San Francisco (UCSF) neuropathology. Eligible low-grade gliomas include: astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Pilocytic astrocytomas are excluded.
• Patient's tumor must have documentation of the presence of an Isocitrate dehydrogenase 1 (IDH1) and/or Isocitrate dehydrogenase 2 (IDH2) mutation of any type.
• Results of 1p/19q chromosomal status and p-PRAS40 testing must be available to permit treatment selection.
• Evaluable disease
• Must begin treatment within 120 days of surgical procedure

You may not qualify if:

• No prior tumor treatment except for surgery at diagnosis, and must have adequately recovered from surgery
• Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus) or to temozolomide
• Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus or temozolomide
• Uncontrolled diabetes mellitus as defined by HbA1c \> 8.0% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary;
• Any severe and/or uncontrolled medical conditions such as: unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease; symptomatic congestive heart failure of New York heart Association Class III or IV; active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable hepatitis B virus(HBV-DNA and/or positive Hepatitis B Surface Antigen (HbsAg), quantifiable hepatitis C virus (HCV-RNA); known severely impaired lung function (spirometry and Diffusing capacity of the lungs for carbon monoxide (DLCO) 50% or less of normal and O2 saturation 88% or less at rest on room air); active, bleeding diathesis;
• Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or inhaled corticosteroids are allowed, and treatment with low dose Decadron (\<= 3mg daily) is allowed;
• Known history of HIV seropositivity;
• Positive serological test results for hepatitis B
• Positive serological test result for hepatitis C
• Recipients of live attenuated vaccines within 1 week of start of treatment and during the study. Avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines;
• History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uterus, or breast, unless the patient has been disease free for \>= 3 years;
• History of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study;
• Currently part of or have participated in any clinical investigation with an investigational therapeutic drug within 1 month prior to dosing;
• Pregnant or nursing (lactating) women;
• Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, who are not willing to use adequate methods of contraception during the study and for 8 weeks after the end of treatment.

Sponsors & Collaborators

• University of California, San Francisco: lead
• Novartis: collaborator

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

Location

Related Links

• Abstract: Neuro Oncol. 2019 Nov; 21(Suppl 6): vi22-vi23

MeSH Terms

Conditions

Astrocytoma; Oligodendroglioma

Interventions

Everolimus; Temozolomide

Condition Hierarchy (Ancestors)

Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Sirolimus; Macrolides; Lactones; Organic Chemicals; Dacarbazine; Triazenes; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Limitations and Caveats

Study was closed prematurely due to slow accrual and loss of drug support.

Results Point of Contact

• Title: Dr. Jennifer Clarke, MD MPH
• Organization: University of California, San Francisco

Jennifer.Clarke@ucsf.edu

(415) 353-2167

Study Officials

• Jennifer Clarke, MD, MPH

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 24, 2013
• First Posted: December 30, 2013
• Study Start: March 19, 2014
• Primary Completion: September 30, 2021
• Study Completion: September 30, 2021
• Last Updated: December 29, 2022
• Results First Posted: December 29, 2022

Record last verified: 2022-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)